Companies

Aditya Puri, former MD of HDFC Bank, joins Strides Group as advisor

Our Bureau. Bengaluru | Updated on July 01, 2021

Former HDFC Bank managing director Aditya Puri (file photo)   -  Shashi Ashiwal

Will also serve as a director of its associate company, Stelis Biopharma

Strides Pharma Science Limited announced that Aditya Puri has joined the Strides Group as an advisor and would also be a director of its associate company, Stelis Biopharma.

Puri’s appointment to the Stelis Board comes as the company transitions from its incubation phase to a consolidation and growth phase to establish itself as a partner of choice globally, with the aim of bringing world-class treatments at affordable costs to patients in both emerging and developed markets.

A stalwart of the Indian banking and financial services industry, Puri was the founder-Managing Director and Chief Executive Officer of HDFC Bank from its inception in 1994 until his retirement from the position in October 2020, earning the distinction of having been the longest-serving head of a private bank in India.

Commenting on the development, Aditya Puri said, “I look forward to working with Arun and building world-class institutions to produce high-quality affordable biotherapeutics and CDMO services including those needed to combat the ongoing Covid-19 pandemic. The Group’s established parentage, global success and headstart in terms of basic infrastructure, give me the opportunity to be involved in and guide Stelis and other Group endeavours in their exciting growth story.”

Arun Kumar, Founder & Chairman of the Board of Strides, said, “Aditya’s illustrious legacy is well-known. Having nurtured HDFC Bank since inception, his deep experience will be extremely valuable for the Strides Group and Stelis in particular. With Stelis poised for its next leg of growth, this is the right time to expand the Board, and ensure robust guidance and governance by the best possible industry minds. I look forward to working with Aditya and leveraging his expertise to take Stelis to new heights.”

Strides Pharma posts ₹102-cr profit in first quarter

 

Published on January 08, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like